Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6950066 | 0.78 | SLC6A2 (0.33) | — | |
| SCHEMBL8331721 | 0.78 | SLC6A2 (0.33) | — | |
| SCHEMBL8331085 | 0.78 | SLC6A2 (0.33) | — | |
| SCHEMBL8469740 | 0.78 | SLC6A2 (0.33) | — | |
| SCHEMBL8333576 | 0.78 | SLC6A2 (0.33) | — | |
| SCHEMBL14432004 | 0.75 | CTSS (0.33) | CTSSCTSK | |
| SCHEMBL14431997 | 0.75 | CTSK (0.45) | CTSSCTSKCTSLCTSB | |
| SCHEMBL5459590 | 0.75 | CTSK (0.45) | CTSSCTSKCTSLCTSB | |
| SCHEMBL19194900 | 0.71 | SLC6A2 (0.33) | — | |
| SCHEMBL26050114 | 0.70 | CPN1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1687296-A1 | ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES | Warner-Lambert Company LLC (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049602-A1 | QUINOLONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049605-A1 | ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | MRPL21, RPN2, FBL | CTSS 687/4885CTSK 490/4885CTSD 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.